Aluminum toxicity in neonatal parenteral nutrition: What can we do?

Heather Ann Wier, Robert J. Kuhn

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Aluminum toxicity has been described in patients of all ages who are receiving a variety of therapies, including dialysis, phosphate-binding medications, and parenteral nutrition (PN). Neonates are at an increased risk of aluminum toxicity because of anatomic, physiologic, and nutrition-related factors not present in other populations. In 2004, the Food and Drug Administration recommended restricting daily aluminum administration to 5 μg/kg/day and now requires that additives used to compound PN have the maximum aluminum content at expiration listed on the product label. Although the pharmacist can work to decrease aluminum toxicity in this population, it remains difficult to reach this threshold.

Original languageEnglish
Pages (from-to)137-140
Number of pages4
JournalAnnals of Pharmacotherapy
Issue number1
StatePublished - Jan 2012


  • Aluminum toxicity
  • Parenteral nutrition

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Aluminum toxicity in neonatal parenteral nutrition: What can we do?'. Together they form a unique fingerprint.

Cite this